Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Introduction: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly symptomatic women <60 years of age or within 10 menopause, safety and tolerability concerns have discouraged HT use due to potential links with perceived increased risk hormone-dependent cancers, an established stroke venous thromboembolism. There is therefore need safe, effective non-hormonal relief vasomotor symptoms (VMS).Areas covered: This narrative review summarizes the dataset accrued fezolinetant, neurokinin-3 receptor (NK3R) antagonist in development menopause-associated VMS.Expert opinion: Altered signaling neuroendocrine circuits at menopause leads VMS wherein NK3R activity plays key modulate thermoregulatory center manner conducive triggering ‘hot flash’ response. Thus, new generation antagonists has entered specifically target mechanistic basis VMS. Fezolinetant most advanced terms stage development. Results date demonstrated rapid substantial reduction frequency severity associated improvements health-related quality life. offer alternative treatment menopause-related